KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Finished Goods (2016 - 2019)

Historic Finished Goods for NovoCure (NVCR) over the last 6 years, with Q2 2019 value amounting to $12.9 million.

  • NovoCure's Finished Goods rose 649.34% to $12.9 million in Q2 2019 from the same period last year, while for Jun 2019 it was $12.9 million, marking a year-over-year increase of 649.34%. This contributed to the annual value of $13.0 million for FY2018, which is 3976.81% up from last year.
  • Latest data reveals that NovoCure reported Finished Goods of $12.9 million as of Q2 2019, which was up 649.34% from $14.4 million recorded in Q1 2019.
  • In the past 5 years, NovoCure's Finished Goods registered a high of $14.4 million during Q1 2019, and its lowest value of $4.9 million during Q3 2015.
  • In the last 5 years, NovoCure's Finished Goods had a median value of $10.9 million in 2017 and averaged $10.3 million.
  • Its Finished Goods has fluctuated over the past 5 years, first skyrocketed by 23280.49% in 2015, then tumbled by 3262.78% in 2017.
  • Over the past 5 years, NovoCure's Finished Goods (Quarter) stood at $5.5 million in 2015, then soared by 120.12% to $12.0 million in 2016, then dropped by 22.47% to $9.3 million in 2017, then soared by 39.77% to $13.0 million in 2018, then decreased by 0.85% to $12.9 million in 2019.
  • Its Finished Goods was $12.9 million in Q2 2019, compared to $14.4 million in Q1 2019 and $13.0 million in Q4 2018.